Inhibition of miR301 enhances Akt-mediated cell proliferation by accumulation of PTEN in nucleus and its effects on cell-cycle regulatory proteins
Metrics: PDF 1415 views | HTML 1767 views | ?
Mayur V. Jain1, Ahmad Shareef1, Wirginia Likus2, Artur Cieślar-Pobuda3, Saeid Ghavami4, Marek J. Łos5,6
1Department of Clinical & Experimental Medicine, Division of Cell Biology Integrative Regenerative Medicine Center (IGEN), Linköping University, Linköping, Sweden
2Department of Human Anatomy, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland
3Institute of Automatic Control, Silesian University of Technology, Gliwice, Poland
4Department of Human Anatomy and Cell Science, College of Medicine, Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada
5Department of Pathology, Pomeranian Medical University, Szczecin, Poland
6LinkoCare Life Sciences AB, Linköping, Sweden
Marek J. Łos, e-mail: [email protected]
Keywords: miR301, PTEN, PI3K, AKT, mTOR
Received: December 31, 2015 Accepted: February 18, 2016 Published: March 8, 2016
Micro-RNAs (miRs) represent an innovative class of genes that act as regulators of gene expression. Recently, the aberrant expression of several miRs has been associated with different types of cancers. In this study, we show that miR301 inhibition influences PI3K-Akt pathway activity. Akt overexpression in MCF7 and MDAMB468 cells caused downregulation of miR301 expression. This effect was confirmed by co-transfection of miR301-modulators in the presence of Akt. Cells overexpressing miR301-inhibitor and Akt, exhibited increased migration and proliferation. Experimental results also confirmed PI3K, PTEN and FoxF2 as regulatory targets for miR301. Furthermore, Akt expression in conjunction with miR301-inhibitor increased nuclear accumulation of PTEN, thus preventing it from downregulating the PI3K-signalling. In summary, our data emphasize the importance of miR301 inhibition on PI3K-Akt pathway-mediated cellular functions. Hence, it opens new avenues for the development of new anti-cancer agents preferentially targeting PI3K-Akt pathway.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.